Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Based on our findings in this work
2023-10-17

Based on our findings in this work as well as the previous published data in the experimental mice model of RSV infection, we suggest that modulation of 12/15 LOX expression and/or blocking of LOX products such as 12(S)-HETE may represent potential pharmacological approaches to prevent or treat vira
-
Introduction Aldose reductase ALR is the
2023-10-17

Introduction Aldose reductase (ALR2) is the first enzyme of the polyol pathway that catalyzes the reduction of glucose to sorbitol utilizing NADPH as a cofactor. The intracellular accumulation of sorbitol, due to increased aldose reductase activity at high blood glucose levels, such as those occurr
-
br Conflict of interest br Acknowledgements
2023-10-17

Conflict of interest Acknowledgements We would like to thank Editage (www.editage.jp) for English language editing. This work was supported by Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Grant Number 24592576. Co-existence of β- and β-adrenergic recept
-
The synthetic route to M developed
2023-10-17

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
Molecular docking simulations were carried out
2023-10-17

Molecular docking simulations were carried out for ligands – in the ACE crystal structure (1O86) and DPP4 crystal structure (2G5P). Comparison of the binding mode of – () with enalaprilat (a) in ACE shows that the phenethyl group (–, enalaprilat) occupies the S1 pocket and the adjacent carboxylic F
-
In this scenario the receptor tyrosine kinase inhibitors TKI
2023-10-17

In this scenario, the receptor tyrosine kinase inhibitors (TKI), sunitinib, an anti-angiogenic agent, was tested in phase III trial, leading to a longer progressing free survival when compared to interferon (median: 11 vs. 5mo, respectively, hazard ratio (HR) = 0.42; 95% CI: 0.32–0.54; Pits Cy5 carb
-
The proposed method was also
2023-10-16

The proposed method was also used to evaluate resistance to natamycin (a natural antibiotic produced by Streptomyces natalensis used for fungal control on cheese surface) of 9 fungi, including those previously mentioned as well as Phoma pinodella UBOCC-A-116004, Candida parapsilosis UBOCC-A-216002,
-
Regardless of the initial treatment most
2023-10-16

Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse
-
rora In this study we have
2023-10-16

In this study, we have generated new FRET reporters to screen all submembrane domains of AT1R for interactions with CaM. We identified a new CaM-binding domain on the receptor’s SMD2 (a.a. 125 – 141), confirmed interactions at SMD4JM (a.a. 309 – 327) and characterized the full interacting domain in
-
Both AD and dyslipidemias are global public health problems
2023-10-16

Both AD and dyslipidemias are global public health problems, and an increase in their incidence over the next decades is expected. Among many triggering elements, the increase in life expectancy is one of the main risk factors associated with the increase in the incidence of AD. Meanwhile, dyslipide
-
When a clinician diagnoses a person
2023-10-16

When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs
-
The direction of glutamate transport
2023-10-16

The direction of glutamate transport by the cell membrane transporter is reversible. As mentioned above, glutamate transport is an electrogenic process associated with a transmembrane ion gradient established by the Na+-K+ pump through hydrolysis of adenosine triphosphate. Under conditions of energy
-
br Materials and methods br Results br Discussion In
2023-10-16

Materials and methods Results Discussion In this study, we have demonstrated that the adiponectin system (genes and proteins) is present in the porcine endometrium (epithelial glandular cells, luminal epithelial mma f and stromal cells) and myometrium (longitudinal and circular muscle laye
-
br Introduction The chronic inflammation
2023-10-16

Introduction The chronic inflammation is one of the leading events involved in the aetiology of many chronic-degenerative diseases including diabetes, atherosclerosis, arthritis and cancer (Coussens and Werb, 2002). Monocytes/macrophages lineage plays an important role during inflammation through
-
br Regulatory mechanisms of ASK activity br The
2023-10-16

Regulatory mechanisms of ASK1 activity The functions of ASK1 in disease ASK1 inhibitor As mentioned above, ASK1 plays a pivotal role in the pathogenesis of various diseases; hence, an ASK1 inhibitor has therapeutic potential. Although inhibitors of the ASK1 downstream kinases p38 and JNK ar
15827 records 249/1056 page Previous Next First page 上5页 246247248249250 下5页 Last page